1Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis, 2006, 26: 162-170.
2Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother, 2004, 48: 3498-3507.
3Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology, 2008, 134: 405-415.
4Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. Hepatology, 2006, 44 (Suppl 1): 222A.
5Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352: 2682-2695.
6Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2004, 351: 1206-1217.
7Sung JY, Lai JY, Zeuzem S, et al. A randomized double-blind phase Ⅱ study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naive patients with chronic hepatitis B: week 52 analysis. J Hepatol, 2003: 38(suppl 2): 25-26.
8Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology, 2005, 129: 528- 536.
9Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol, 2006, 44: 422-431.
10Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology, 2007, 46: 254-265.
2Song BC,Suh DJ,Lee HC,et al.Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea[J].Hepatology,2000,32(4 Pt1):803.
3Lee HW,Lee HJ,Hwang JS,et al.Lamivudine maintenance beyond one year after HBe Ag Seroconversion is a major factor for sustained virologic response in HBe Agpositive chronic Hepatitis B[J].Hepatology,2010,51(2):415.
4Chien RN,Yeh CT,Tsai SL,et al.Determinants for sustained HBe Ag response to lamivudine therapy[J].Hepatology,2003,38(5):1 267.
